Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

E-ISSN： 1875-9114|35|10|979-979

ISSN： 0277-0008

Source： PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol.35, Iss.10, 2015-10, pp. : 979-979

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 4, 2015-04 ,pp. : 412-423

John Wiley & Sons Inc

Access to resources Recommend Favorite

Vedolizumab for ulcerative colitis and Crohn's disease

PRESCRIBER, Vol. 26, Iss. 10, 2015-05 ,pp. : 22-24

John Wiley & Sons Inc

Access to resources Recommend Favorite

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 2, 2015-07 ,pp. : 188-202

John Wiley & Sons Inc

Access to resources Recommend Favorite

Predicting corticosteroid‐free endoscopic remission with vedolizumab in ulcerative colitis

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 6, 2018-03 ,pp. : 763-772

John Wiley & Sons Inc

Access to resources Recommend Favorite

Novel treatment options for ulcerative colitis

By Vaughn Byron P Moss Alan C

Clinical Investigation, Vol. 3, Iss. 11, 2013-11 ,pp. : 1057-1069

Future Science

Access to resources Recommend Favorite